- Home
- BJ vs BBIO Comparison
BJ vs BBIO Comparison
Compare BJ & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJ | BBIO |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 15.3B |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BJ | BBIO |
|---|---|---|
| Price | $100.26 | $69.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 25 |
| Target Price | ★ $108.36 | $83.96 |
| AVG Volume (30 Days) | ★ 1.8M | 1.8M |
| Earning Date | 03-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.50 | N/A |
| EPS | ★ 4.38 | N/A |
| Revenue | ★ $21,457,274,000.00 | $502,076,000.00 |
| Revenue This Year | $9.20 | $88.16 |
| Revenue Next Year | $6.18 | $74.13 |
| P/E Ratio | $23.00 | ★ N/A |
| Revenue Growth | 4.66 | ★ 126.26 |
| 52 Week Low | $86.68 | $28.33 |
| 52 Week High | $121.10 | $84.94 |
Technical Indicators
Market Signals| Indicator | BJ | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 48.95 |
| Support Level | $94.23 | $61.95 |
| Resistance Level | $100.33 | $78.83 |
| Average True Range (ATR) | 2.98 | 3.02 |
| MACD | 0.32 | 0.39 |
| Stochastic Oscillator | 84.45 | 24.66 |
Price Performance
Historical ComparisonAbout BJ BJ's Wholesale Club Holdings Inc.
BJ's Wholesale Club, founded in 1984, operates a membership-based warehouse club model primarily along the US East Coast, with roughly 250 clubs and a growing domestic presence across 21 states. In fiscal 2024, the company generated over $20 billion in revenue. BJ's offers a value-oriented assortment skewed toward grocery, perishables, and consumables (71% of sales), general merchandise (11%), and gasoline (18%). Its business model is supported by recurring membership fee income and private-label brands such as Wellsley Farms and Berkley Jensen.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.